RxDoctor Payments Data

Wendy Donaugh

Family · Billings, MTNPI 1336523836

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,006in general payments, 2019–2025

Across 169 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$687
  • AbbVie$408
  • UCB, Inc.$335
  • Johnson & Johnson$273
  • AstraZeneca$251
  • Novartis$189
  • plus $864 from 14 others

What the payments were for

  • Food & beverage$2,97299%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,006 in reported general payments places this provider in the 90th percentile of 481 family providers in Montana.

See all family providers in Montana

Medicare billing

Part B allowed, 2024
$363,388
Medicare patients
98
Services billed
38,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CortrophinCorticotropin17$1,225,185
RinvoqUpadacitinib14$92,272
Hydroxychloroquine Sulfate93$3,771
MethotrexateMethotrexate Sodium102$1,671
Pilocarpine Hcl20$1,592
Leflunomide17$1,427
Meloxicam63$425
Prednisone90$422
Celecoxib18$400
Cyclobenzaprine Hcl38$226
Allopurinol37$223
Gabapentin11$143
Tramadol Hcl11$85
Tizanidine Hcl12$54
Pregabalin22$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$408$92,27214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 481 family providers in Montana.

Other family in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →